Rani Therapeutics reports FY2024 net loss of $56.6M; cash to Q3 2025; RT-114 preclinical data positive

Rani Therapeutics Holdings, Inc.

2025-Q1 EPS reported -$0.22 revenue$172,000

FY2024 net loss of $56.6M vs $67.9M in 2023; cash and marketable securities $27.6M, expected to fund operations into Q3 2025.
Preclinical data for RT-114 (GLP-1/GLP-2 dual agonist) shows 111% relative bioavailability vs subcutaneous, with bioequivalence and comparable weight loss.
Preclinical data for semaglutide oral via RaniPill HC (RT-116) shows bioavailability, PK, and weight loss comparable to subcutaneous.
Phase 1 study of RT-114 for obesity expected to initiate mid-2025; partnership with ProGen for co-development of RT-114.
Impairment loss of $3.7M on construction-in-progress equipment; R&D expenses down $12.9M YoY due to workforce reduction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.